Motif Bio is focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant bacteria. Our initial focus is on iclaprim, a targeted antibiotic with activity against MRSA.

Iclaprim Development Plan Targets High-Risk MRSA Patients